<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28565">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02097316</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A00792-43</org_study_id>
    <nct_id>NCT02097316</nct_id>
  </id_info>
  <brief_title>Feasibility Study of the JewelPump Version 3</brief_title>
  <official_title>Feasibility Study of the JewelPump Version 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted, in cross-over with a time interval of at least 2 days between 2
      treatment periods. Patients will be randomized into 2 groups According to the order of the
      randomization, patients will bear the JewelPump for 5 days, followed by a period of 5 days
      of treatment with their usual pumps.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The JewelPump (Debiotech) will be compared to the conventional pumps. Patients will treated
      with the JewelPump during 5 days, and with their usual pump during 5 other days.

      The study will be conduct with 15 patients at the following investigation centers : Corbeil
      Hospital, CHU of Strasbourg, and CHRU of Marseille.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time spent in glycemic area 70-180 mg / dl, measured continuously for 5 days with a continuous glucose monitoring (CGM) DEXCOM G4</measure>
    <time_frame>up to 5 days of each treatment period</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate the non-inferiority of JewelPump compared to the usual pump patient, on glycemic control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time spent in the strict glycemic area 80-140 mg / dl</measure>
    <time_frame>up to 5 days of each treatment period</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate the superiority of JewelPump versus usual pump;</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time spent below 70 mg / dl</measure>
    <time_frame>up to 5 days in each treatment period</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Time spent above 180mg/dl;</measure>
    <time_frame>up to 5 days in each treatment period</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>JewelPump</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JewelPump for the first treatment period followed by the usual pump for the second treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual insulin pump</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the arm 2, will have the usual insulin pump for the first treatment period, followed with the second period which they will have the JewelPump.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JewelPump</intervention_name>
    <arm_group_label>JewelPump</arm_group_label>
    <arm_group_label>Usual insulin pump</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>usual insulin pump</intervention_name>
    <arm_group_label>JewelPump</arm_group_label>
    <arm_group_label>Usual insulin pump</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients type 1 diabetics treated by external insulin pump;

          -  Patients with HbA1c &lt; 8.5%

          -  Patients who signed consent

        Exclusion Criteria:

          -  Patients type 2 diabetics

          -  Patients who have all serious diseases that could interfere with the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvia FRANC, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Sud Francilien</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathalie JEANDIDIER, Pr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Denis RACCAH, Pr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillaume CHARPENTIER, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume CHARPENTIER, MD</last_name>
    <phone>+33164968654</phone>
    <email>pres@ceritd.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Sud Francilien</name>
      <address>
        <city>Evry</city>
        <zip>91000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvia FRANC, MD</last_name>
      <phone>+33161697072</phone>
    </contact>
    <investigator>
      <last_name>Sylvia FRANC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Marseille-Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pauline SCHAEPELYNCK, MD</last_name>
      <phone>+334 91 74 55 00</phone>
      <email>pauline.schaepelynck@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Denis RACCAH, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline SCAEPELYNCK, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 24, 2014</lastchanged_date>
  <firstreceived_date>September 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glycemic control</keyword>
  <keyword>JewelPump accuracy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
